U.S. Markets close in 5 hrs 44 mins
  • S&P 500

    4,121.12
    -7.68 (-0.19%)
     
  • Dow 30

    33,710.99
    -89.61 (-0.27%)
     
  • Nasdaq

    13,829.18
    -71.01 (-0.51%)
     
  • Russell 2000

    2,224.36
    -19.11 (-0.85%)
     
  • Crude Oil

    60.49
    +1.17 (+1.97%)
     
  • Gold

    1,732.80
    -12.00 (-0.69%)
     
  • Silver

    24.84
    -0.49 (-1.92%)
     
  • EUR/USD

    1.1913
    +0.0009 (+0.0715%)
     
  • 10-Yr Bond

    1.6760
    +0.0100 (+0.60%)
     
  • Vix

    17.64
    +0.95 (+5.69%)
     
  • GBP/USD

    1.3746
    +0.0041 (+0.2955%)
     
  • USD/JPY

    109.3990
    -0.2510 (-0.2289%)
     
  • BTC-USD

    60,223.13
    +583.98 (+0.98%)
     
  • CMC Crypto 200

    1,288.29
    -6.29 (-0.49%)
     
  • FTSE 100

    6,904.79
    -10.96 (-0.16%)
     
  • Nikkei 225

    29,538.73
    -229.33 (-0.77%)
     

GRFS or ZTS: Which Is the Better Value Stock Right Now?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Grifols has a Zacks Rank of #2 (Buy), while Zoetis has a Zacks Rank of #3 (Hold) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that GRFS has an improving earnings outlook. But this is just one piece of the puzzle for value investors.

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

GRFS currently has a forward P/E ratio of 12.96, while ZTS has a forward P/E of 40.24. We also note that GRFS has a PEG ratio of 1.32. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ZTS currently has a PEG ratio of 3.76.

Another notable valuation metric for GRFS is its P/B ratio of 1.62. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, ZTS has a P/B of 22.32.

These are just a few of the metrics contributing to GRFS's Value grade of A and ZTS's Value grade of C.

GRFS has seen stronger estimate revision activity and sports more attractive valuation metrics than ZTS, so it seems like value investors will conclude that GRFS is the superior option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Grifols, S.A. (GRFS) : Free Stock Analysis Report
 
Zoetis Inc. (ZTS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research